CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
filgrastim +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00020176
NCT00020176Phase 2Completed
CompareCT.gov

Allogeneic Breast Protocol 1: T-Cell Depleted Allogeneic Blood Stem Cell Transplantation Using an Immunoablative Conditioning Regimen in Metastatic Breast Cancer

National Cancer Institute (NCI)·interventional·Posted Jan 27, 2003·Updated Jun 20, 2013

In Brief

A Phase 2 clinical trial evaluating filgrastim, therapeutic allogeneic lymphocytes, and 4 other interventions for Breast Cancer. Completed, across 2 sites.

Detailed Summary

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic peripheral stem cell transplantation in treating patients who have stage IV breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartJun 1, 2000
Study CompletionAug 1, 2007
TodayJul 2, 2026
Posted 23.4 years ago

Interventions

filgrastimbiological

therapeutic allogeneic lymphocytesbiological

cyclophosphamidedrug

cyclosporinedrug

fludarabine phosphatedrug

peripheral blood stem cell transplantationprocedure